Insys to Pay $225 Million to Settle Opioid-Sales Probe
- Deal includes $195 million to resolve claim by whistle-blowers
- Insys founder Kapoor facing prison for role in bribing doctors
Photographer: Antoine Antoniol/Bloomberg
This article is for subscribers only.
Insys Therapeutics Inc., grappling with the prospect of bankruptcy after its founder was convicted on racketeering charges, agreed to pay $225 million to settle U.S. claims that the drug maker illegally sold opioid-based painkillers.
Under terms of the deal, Insys will pay $195 million to resolve whistle-blower claims tied to a scheme that involved bribing doctors to over-prescribe the company’s powerful painkiller, Subsys, federal prosecutors said. The company also will pay a $2 million criminal fine and forfeit $28 million in cash.